News | June 03, 2024
Supriya Lifescience FY24 PAT up 32%
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
The Profit After Tax (PAT) for Q4 FY24 at Rs 36.40 crore, compared to Rs 38.23 crore in Q4 FY23
EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%
Outlook 2024 remains flat CER sales growth and CORE EBITDA margin of high 20s
Lonza plans to invest approximately CHF 500 million to upgrade the facility
Group sales came in at 47.637 billion euros, down 1.2% on a currency- and portfolio-adjusted basis
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
Zydus’s revenue growth was led by India and EU formulations businesses in addition to that in the emerging markets.
EBITDA for Q3 FY24 almost tripled to reach Rs. 41.49 crore
The company recently received CEP certificate approval for Losartan Potassium by EDQM
Subscribe To Our Newsletter & Stay Updated
